CD44 and breast carcinoma: A somewhat similar approach was recently used by Snyder et al. [16] who used quantum-dot immunofluorescence and spectral unmixing to evaluate CD44+ and CD24− cells in tissue samples of breast carcinoma; the authors showed that CD44+/CD24− cells have distinctive properties in primary human breast carcinomas in terms of proliferation rate and resistance to chemotherapy.